What is the appropriate management for a 75-year-old female with a Morganella morganii urinary tract infection that is resistant to all antibiotics except meropenem?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Pan-Resistant Morganella morganii UTI in a 75-Year-Old Female

Treat with intravenous meropenem 1 gram every 8 hours for 5-7 days, with dose adjustment based on renal function. This is the only viable option given pan-resistance except to meropenem, and carbapenems remain the cornerstone for multidrug-resistant Enterobacterales urinary tract infections.

Dosing and Duration

For complicated UTI due to carbapenem-resistant or multidrug-resistant Enterobacterales, the 2022 guidelines recommend 5-7 days of treatment 1. Given this is Morganella morganii (an Enterobacterales family member) with extreme resistance:

  • Standard dosing: Meropenem 1 gram IV every 8 hours 2
  • Critical consideration for elderly: At 75 years old, assess creatinine clearance immediately 2
    • If CrCl ≤50 mL/min: dose reduction is mandatory 2
    • If CrCl 26-50 mL/min: 1 gram every 12 hours
    • If CrCl 10-25 mL/min: 500 mg every 12 hours
    • If CrCl <10 mL/min: 500 mg every 24 hours

Key Clinical Considerations

Why Meropenem Over Other Options

The 2024 EAU guidelines specify that for uncomplicated pyelonephritis with multidrug-resistant organisms, carbapenems should only be considered when early culture results indicate resistance to other agents 3. Your patient meets this criterion with pan-resistance. Among carbapenems:

  • Meropenem achieves excellent urinary concentrations 2
  • The FDA label confirms efficacy for complicated UTIs 2
  • Recent data shows meropenem maintains >98% susceptibility against M. morganii isolates 4

Combination Therapy Consideration

While monotherapy is appropriate for UTI, consider adding an aminoglycoside (gentamicin 5-7 mg/kg/day IV once daily) if the patient is clinically unstable 1. The 2022 MDR guidelines specifically recommend aminoglycosides for complicated UTIs due to carbapenem-resistant Enterobacterales 1. Recent research demonstrates synergy between meropenem and aminoglycosides against resistant M. morganii 5.

However, in a stable 75-year-old with isolated UTI, meropenem monotherapy is sufficient 1. Combination therapy increases nephrotoxicity risk in elderly patients.

Critical Pitfalls to Avoid

1. Seizure Risk in Elderly

Meropenem carries seizure risk, particularly in elderly patients with renal impairment 2. Monitor for:

  • Focal tremors, myoclonus, or altered mental status
  • Continue any existing anti-convulsant therapy
  • If seizures occur, reduce dose or discontinue 2

2. Drug Interaction Alert

If the patient takes valproic acid or divalproex for seizure control, do NOT use meropenem 2. Carbapenems dramatically reduce valproic acid levels, causing breakthrough seizures. In this scenario, you would need infectious disease consultation for alternative strategies, though options are extremely limited with pan-resistance.

3. Thrombocytopenia Monitoring

In elderly patients with renal impairment, monitor platelet counts as thrombocytopenia has been reported with meropenem 2.

4. Source Control

Ensure no urinary obstruction, retained catheter, or abscess. The 2024 EAU guidelines emphasize that complicated UTI management requires addressing anatomic abnormalities 3. Obtain renal ultrasound if not already done.

Resistance Surveillance Concerns

Recent data shows alarming trends in M. morganii resistance:

  • Carbapenem resistance increased significantly after 2022 4
  • Some isolates now harbor KPC-2, NDM-1, or OXA-48 carbapenemases 6
  • Mortality from M. morganii bacteremia reaches 41% 7

If the patient fails to improve within 72 hours, repeat cultures and consider:

  1. Carbapenemase production testing (though treatment options are nearly exhausted)
  2. Infectious disease consultation
  3. Potential for colistin-based combination therapy, though M. morganii has intrinsic colistin resistance 5

Alternative Considerations if Meropenem Fails

Given pan-resistance, options are severely limited. The 2022 MDR guidelines suggest for CRE with limited options 1, 8:

  • Ceftazidime-avibactam 2.5 g IV q8h (if available and susceptible)
  • Polymyxin-based combinations (though M. morganii is intrinsically colistin-resistant)
  • High-dose extended-infusion meropenem (3-hour infusion) if MIC ≥8 mg/L 1

However, these are salvage options requiring susceptibility confirmation.

Monitoring Parameters

  • Daily clinical assessment for symptom resolution
  • Repeat urinalysis after 48-72 hours if not improving
  • Renal function monitoring (especially in elderly) 2
  • Neurological assessment for seizure precursors 2
  • Platelet count if renal impairment present 2

The treatment duration of 5-7 days assumes prompt clinical response 1. If delayed response or bacteremia develops, extend to 10-14 days 1, 9.

References

Related Questions

What is the recommended therapy for a Morganella morganii infection in a patient allergic to penicillin?
How should I manage a urine culture that isolates Morganella morganii subsp. morganii at >100,000 CFU/mL (significant) and a second Gram‑negative bacillus at <10,000 CFU/mL (likely contaminant)?
What complications can arise from Morganella morganii infections?
What is the appropriate oral therapy for a urinary tract infection caused by Morganella morganii and Proteus mirabilis?
What is the appropriate treatment for a recurrent urinary tract infection caused by Morganella morganii and Staphylococcus aureus?
What are the methods to identify safe, high-quality dietary supplements?
Can you write a SOAP note for a 57‑year‑old postmenopausal female new to the clinic, asymptomatic, requesting a routine wellness exam with labs and mammogram, unknown last mammogram and Pap dates, and include appropriate CPT and ICD‑10 codes?
What recommendations should be made for a 45-year-old male with type 1 diabetes, orthostatic hypotension, neurogenic bladder, recent urinary tract infection, chronic constipation, protein‑calorie malnutrition, and newly added tamsulosin (Flomax) to address medication safety, bladder management, bowel regimen, nutrition, fall risk, and overall care?
What are the indications for using loperamide?
What is the recommended treatment for an oblique fracture of the distal fibular metaphysis displaced by at least 2 mm?
I have been off lurasidone (Latuda) for 16 days; can I smoke marijuana?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.